Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY Stefan Borgwardt, University of Lübeck, Germany

***CORRESPONDENCE** Kuan-Pin Su ⊠ cobolsu@gmail.com

SPECIALTY SECTION

This article was submitted to Neuroimaging, a section of the journal Frontiers in Psychiatry

RECEIVED 23 November 2022 ACCEPTED 23 December 2022 PUBLISHED 16 January 2023

CITATION

Liang C-S, Chou P-H, Wang S-C, Sack AT and Su K-P (2023) Editorial: Non-invasive brain stimulation in psychiatric disorders: From bench to bedside. *Front. Psychiatry* 13:1106558. doi: 10.3389/fpsyt.2022.1106558

COPYRIGHT

© 2023 Liang, Chou, Wang, Sack and Su. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Editorial: Non-invasive brain stimulation in psychiatric disorders: From bench to bedside

Chih-Sung Liang^{1,2}, Po-Han Chou³, Shao-Cheng Wang^{4,5}, Alexander T. Sack^{6,7,8,9} and Kuan-Pin Su^{10,11,12*}

¹Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ²Department of Psychiatry, National Defense Medical Center, Taipei, Taiwan, ³Department of Psychiatry, China Medical University Hsinchu Hospital, China Medical University, Hsinchu, Taiwan, ⁴Department of Psychiatry, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, ⁵Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States, ⁶Section Brain Stimulation and Cognition, Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Netherlands, ⁷Maastricht Brain Imaging Centre (MBIC), Maastricht, Netherlands, ⁸Centre for Integrative Neuroscience (CIN), Maastricht University, Maastricht, Netherlands, ⁹Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Brain + Nerve Centre, Maastricht University, Medical Centre+ (MUMC+), Maastricht, Netherlands, ¹⁰College of Medicine, China Medical University, Taichung, Taiwan, ¹¹Mind-Body Interface Laboratory (MBI-Lab), China Medical University and Hospital, Taichung, Taiwan, ¹²An-Nan Hospital, China Medical University, Tainan, Taiwan

KEYWORDS

noninvasive brain stimulation, transcranial magnetic stimulation, transcranial direct current stimulation, non-regional specificity, rTMS, tDCS

Editorial on the Research Topic

Non-invasive brain stimulation in psychiatric disorders: From bench to bedside

The development of effective treatment modality for psychiatric disorders is an enduring goal of translational research and evidence-based medicine. In recent decades, progress in neuroscience has identified the dysfunctional brain circuits and networks that may underpin the pathogenesis of psychiatric disorders (1). Non-invasive brain stimulation (NIBS) is a set of techniques that can modulate the excitability of large-scale networks in the brain (2). Studies have shown promising results in circuit-based psychiatric treatments in either diagnosis- or symptom-based clinical conditions (3–5).

The current Special Issue, *Non-invasive brain stimulation in psychiatric disorders: From bench to bedside*, in Frontiers in Psychiatry, is dedicated to collect high-quality studies that explore the possible mechanisms for the therapeutic effects of NIBS, including molecular, genetics, neuroimaging, and neurophysiological aspects. The relevance for application of transcranial magnetic stimulation (TMS) in treating psychiatric disorders is driven by the development of new protocols and sequences (2). The Food and Drug Administration agency of the United States approved rTMS as a treatment for medication-resistant patients with MDD in 2008 (6). The therapeutic effects of repetitive transcranial magnetic stimulation (rTMS) were also observed in other psychiatric conditions, including MDD (Harika-Germaneau et al.; Spitz et al.), suicidal ideation (Huang et al.), smoking cessation (Chen et al.), and methamphetamine use disorder (Mikellides et al.). Unlike TMS, TES uses low intensity currents to modulate the excitability of targeted networks in the brain. TES is an umbrella term for a variety of different stimulation modalities, such as transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation.

Evidence supports TES as a therapeutic tool in depression (Chang et al.), attention-deficit/hyperactivity disorder (Sobral et al.), and social cognition in schizophrenia (Kannen et al.). These findings from clinical trials and practical experiences suggest that one of the strength of NIBS may lie in its non-regional specificity.

The circuit-based neuromodulation of NIBS may explain the heterogeneity of psychiatric disorders than can be treated with TMS/TES (Figure 1). For example, high-frequency rTMS over left dorsolateral prefrontal cortex (DLPFC) or low-frequency rTMS over right DLPFC are usually applied in the treatment of MDD (Yamada et al.); however, targeting other brain regions also revealed therapeutic effects for MDD, such as ventromedial prefrontal cortex (PFC), orbitofrontal cortex, and ventrolateral PFC (7). The magnetic stimuli applied may regulate the activity of local circuits in the interneurons including fibers projecting to other distant brain regions, which depend on the intrinsic properties and geometrical orientation of the fibers within the stimulated brain region (8). The interconnection between networks of the brain may thus also



explain the non-regional specificity of NIBS effects for the same psychiatric disorder.

In addition, stimulating left DLPFC showed therapeutic effects not only for MDD but also in obsessive-compulsive disorder (9), suicidal ideation (Huang et al.), and methamphetamine use disorder (Mikellides et al.). The neuromodulation can be considered a "topdown" intervention, working at the level of brain networks and then affecting neurogenesis, neuroplasticity, and neurocircuitry (8, 10). For example, a recent study using TMS applied to the ventrolateral PFC elicited changes in the amygdala activity (11). The amygdala processes valenced stimuli, influences emotion, and contributes to a wide array of behavioral and brain disorders (12). Therefore, the top-down neuromodulation of TMS on the amygdala may enable a specific brain region stimulation for the treatment of numerous psychiatric disorders showing aberrant activity in the amygdala, such as MDD, anxiety, and posttraumatic stress disorder (11). Importantly, the therapeutic mechanisms of rTMS also involve neurotransmitter systems (e.g., serotonin, dopamine), neurotrophic factors, anti-inflammatory protein, and various molecular pathways (e.g., extracellular signal-regulated kinase 1/2, endocannabinoid systems) (8, 13, 14). Therefore, the cortical-subcortical structural and functional connections as well as various gene/protein expression and pharmacological modulation may all support the non-regional specificity of NIBS effects for various psychiatric disorders.

Take genetic molecular mechanisms for example, preliminary evidence suggests that the neurobiological effects of gene activation/regulation, *de novo* protein expression, synaptic morphological changes, homeostatic processes and glial function might underlies the long-term after effects of NIBS (15). Althoufh the effects of rTMS may produce long-term therapeutic effects on various psychiatric disorders (15), evidence suggests that rTMS pattern, intensity, frequency, train duration, intertrain interval, intersession interval, pulse and session number, pulse width, and pulse shape can alter motor excitability, long term potentiation-like facilitation, and the clinical antidepressant response (16). The response of rTMS varied widely among depressed patients. A study including 1,132 participants reported that around a half of patients could not achieve treatment response after rTMS treatment (Caulfield and Brown). Therefore, exploration of treatment predictors could help guide the choice of NIBS protocols that are more effective in precision medicine. A naturalistic observational study found that early improvement of depression can be a useful predictor for treatment response for rTMS treatment (Harika-Germaneau et al.). Another study examined clinical and neuroimaging biomarkers of treatment response with rTMS among treatment-resistant depression (6). The reported predictors included depression type, gender, depression severity, and the average volume of the left part of the superior frontal and the caudal middle frontal regions (6).

Advances in psychiatric practice lie in translating evidence from bench to beside. A better understanding of the neurobiological mechanism of NIBS has become an important piece in modern psychiatric practice. The non-region specificity of NIBS provides a window into circuit-based treatment for numerous psychiatric disorders. We believe the findings of the Special Issue could inspire future research to improve psychiatric treatment with precision NIBS applications.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Chang JP, Su KP. Nutrition and immunology in mental health: precision medicine and integrative approaches to address unmet clinical needs in psychiatric treatments. *Brain Behav Immun.* (2020) 85:1–3. doi: 10.1016/j.bbi.2019.09.022

2. Haber SN, Tang W, Choi EY. Circuits, networks, and neuropsychiatric disease: transitioning from anatomy to imaging. *Biol Psychiatry*. (2020) 87:318–27. doi: 10.1016/j.biopsych.2019.10.024

3. Boes AD, Kelly MS, Trapp NT, Stern AP, Press DZ, Pascual-Leone A. Noninvasive brain stimulation: challenges and opportunities for a new clinical specialty. *J Neuropsychiatry Clin Neurosci.* (2018) 30:173–9. doi: 10.1176/appi.neuropsych.17110262

4. Chu C-S, Li C-T, Brunoni AR, Yang F-C, Tseng P-T, Tu Y-K, et al. Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer's disease and mild cognitive impairment: a component network meta-analysis. *J Neurol Neurosurg Psychiatry.* (2021) 92:195–203. doi: 10.1136/jnnp-2020-323870

5. Siddiqi SH, Taylor SF, Cooke D, Pascual-Leone A, George MS, Fox MD. Distinct symptom-specific treatment targets for circuit-based neuromodulation. *Am J Psychiatry.* (2020) 177:435–46. doi: 10.1176/appi.ajp.2019.190 90915

6. McTeague LM, Rosenberg BM, Lopez JW, Carreon DM, Huemer J, Jiang Y, et al. Identification of common neural circuit disruptions in

emotional processing across psychiatric disorders. *Am J Psychiatry.* (2020) 177:411–21. doi: 10.1176/appi.ajp.2019.18111271

7. Chou P-H, Lin Y-F, Lu M-K, Chang H-A, Chu C-S, Chang WH, et al. Personalization of repetitive transcranial magnetic stimulation for the treatment of major depressive disorder according to the existing psychiatric comorbidity. *Clin Psychopharmacol Neurosci.* (2021) 19:190–205. doi: 10.9758/cpn.2021.19.2.190

8. Zhang M, Wang R, Luo X, Zhang S, Zhong X, Ning Y, et al. Repetitive transcranial magnetic stimulation target location methods for depression. *Front Neurosci.* (2021) 15:695423. doi: 10.3389/fnins.2021.695423

9. Peng Z, Zhou C, Xue S, Bai J, Yu S, Li X, et al. Mechanism of repetitive transcranial magnetic stimulation for depression. *Shanghai Arch Psychiatry.* (2018) 30:84. doi: 10.11919/j.issn.1002-0829.217047

10. Chou PH, Sack AT, Su KP. Targeting three brain regions (Bilateral SMA, Left and Right DLPFC) sequentially in one session using combined repetitive transcranial magnetic stimulation and intermittent theta-burst stimulation in treatment-refractory obsessive-compulsive disorder: a case report. *Clin Psychopharmacol Neurosci.* (2022) 20:773–6. doi: 10.9758/cpn.2022.20.4.773

11. Farnad L, Ghasemian-Shirvan E, Mosayebi-Samani M, Kuo MF, Nitsche MA. Exploring and optimizing the neuroplastic effects of anodal transcranial direct current

stimulation over the primary motor cortex of older humans. *Brain Stimul.* (2021) 14:622–34. doi: 10.1016/j.brs.2021.03.013

12. Sydnor VJ, Cieslak M, Duprat R. Cortical-subcortical structural connections support transcranial magnetic stimulation engagement of the amygdala. *Sci Adv.* (2022) 8:eabn5803. doi: 10.1126/sciadv.abn5803

13. Janak PH, Tye KM. From circuits to behaviour in the amygdala. *Nature*. (2015) 517:284–92. doi: 10.1038/nature14188

14. Baeken C, De Raedt R. Neurobiological mechanisms of repetitive transcranial magnetic stimulation on the underlying neurocircuitry in unipolar depression.

Dialogues Clin Neurosci. (2011) 13:139–45. doi: 10.31887/DCNS.2011.13.1/cb aeken

15. Chou P-H, Lu M-K, Tsai C-H, Hsieh W-T, Lai H-C, Shityakov S, et al. Antidepressant efficacy and immune effects of bilateral theta burst stimulation monotherapy in major depression: a randomized, double-blind, sham-controlled study. *Brain Behav Immun.* (2020) 88:144–50. doi: 10.1016/j.bbi.2020.06.024

16. Cirillo G, Di Pino G, Capone F, Ranieri F, Florio L, Todisco V, et al. Neurobiological after-effects of non-invasive brain stimulation. *Brain Stimul.* (2017) 10:1–18. doi: 10.1016/j.brs.2016.11.009